BASEL, Switzerland, Aug. 17, 2023 /PRNewswire/ -- Roche announced today that it has a new addition to the cobas® connection modules (CCM), the CCM Vertical, allowing transportation of samples on overhead conveyors.* This solution allows for CCM conveyors to cross walkways, connecting different work areas and keeps (emergency) exits accessible. Samples can also be transported up or down to different levels.
Given the ever-changing needs of the healthcare system, the demand for automation continues to surge, driven by shortages in skilled personnel, escalating throughput demands and the need for faster results and reduced errors. In addition space limitations in laboratories present a significant hurdle and it can be a challenge to increase the testing capacity.
"Given the dynamic requirements of the healthcare system, laboratories and clinicians are expected to optimise laboratory operations and efficiencies while improving patient care," said Ann Costello, Head of Roche Diagnostics Solutions at Roche Diagnostics. "We are excited about CCM Vertical, it simplifies and streamlines testing for laboratories of all sizes, throughputs and disciplines, while supporting clinical decision-making to improve patient care."
CCM Vertical addresses these difficulties, it is a modular and flexible vertical transportation solution which consists of elevator units, overhead conveyors and overhead turn units. It seamlessly integrates with an existing CCM solution without compromising quality, reliability and performance, in the same way as the CCM horizontal track. CCM Vertical offers multidisciplinary connectivity through floors and ceilings, enabling floor to floor transportation. The space constraints in laboratories where previously there was not even room for a suitable solution, will now be effectively addressed with the multidisciplinary connectivity across many floors and rooms.
About CCM Vertical
This solution is one of the broader laboratory automation offerings delivered by Roche which can be customized for low-, mid- and high-volume laboratories with the ability to facilitate on-site expansion as required. With this solution pre- and post-analytical tasks are automated, offering maximum efficiency through flexible standalone solutions. It significantly reduces manual steps in the laboratory, enhancing error handling, safety and process quality. In addition it also offers transportation. Physically connecting different instruments allows for maximum predictability of time to test results.
The solution consists of the following main (modular) components:
A full list of Roche's laboratory automation offerings is available here.
*Availability of the CCM Vertical may vary depending on local market requirements.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information please contact
Euan Cameron, Roche Diagnostics Solutions
Phone: + 41 79 948 54 49
e-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$35.70 |
Daily Change: | -0.11 -0.31 |
Daily Volume: | 174,535 |
Market Cap: | US$197.060B |
November 12, 2024 November 05, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB